Summit Therapeutics’ ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
Latest Ratings for SMMT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2020 | HC Wainwright & Co. | Downgrades | Buy | Neutral |
| Mar 2020 | HC Wainwright & Co. | Initiates Coverage On | Buy | |
| Jun 2018 | Janney Montgomery Scott | Downgrades | Buy | Neutral |
